1. Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma
   Hyeyoon Chang et al, 2015, Annals of Diagnostic Pathology CrossRef
2. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy
   L Liang et al, 2016, Oncogene CrossRef
3. Current Strategies for Pharmacokinetic Optimization
   Uli Binder et al, 2015, Biobetters CrossRef
4. Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression
   Zeren Sun et al, 2024, Journal of Medicinal Chemistry CrossRef
5. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor
   J. Wang et al, 2017, Clinical and Translational Oncology CrossRef
6. Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
   Meghan Grojean et al, 2021, Journal of Cellular and Molecular Medicine CrossRef
7. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways
   Haiyong Wang et al, 2017, BMC Cancer CrossRef
8. Characterization of human gastric adenocarcinoma cell lines established from peritoneal ascites
   Bożenna Mytar et al, 2018, Oncology Letters CrossRef
9. Predictive biomarkers in gastric cancer
   C. Röcken, 2023, Journal of Cancer Research and Clinical Oncology CrossRef
10. The challenge of developmental therapeutics for adrenocortical carcinoma
    Ricardo Costa et al, 2016, Oncotarget CrossRef
11. Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma
    Xiaobin Wang et al, 2021, Journal of Cellular and Molecular Medicine CrossRef
12. ESM1 Interacts with c-Met to Promote Gastric Cancer Peritoneal Metastasis by Inducing Angiogenesis
    Jiaoyang Yang et al, 2023, Cancers CrossRef
13. Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells
    Rebecca D. Schroeder et al, 2017, Oncotarget CrossRef
14. Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas
    Chrysovalantou Mihailidou et al, 2017, Biochimie CrossRef
15. MET in gastric cancer – discarding a 10% cutoff rule
    Marie‐Luise Metzger et al, 2016, Histopathology CrossRef
16. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
    Jun Lu et al, 2015, Journal of Translational Medicine CrossRef
17. Molecular Mechanisms in Gastric Carcinogenesis
    Jonathan Cools-Lartigue et al, 2015, Gastric Cancer CrossRef
18. FGFR and inhibitors
    Xiaokun Li, 2024, Fibroblast Growth Factors CrossRef
19. Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib
    JIN-AN MA et al, 2015, Molecular Medicine Reports CrossRef
20. Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy
    Zhen Xu et al, 2019, Journal of Molecular Modeling CrossRef
21. Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity
    Tianwei Zhang et al, 2015, PLOS ONE CrossRef
22. Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target
    Maria Trovato et al, 2017, Biomarker Insights CrossRef
23. Peptidomimetic suppresses proliferation and invasion of gastric cancer cells by fibroblast growth factor 2 signaling cascade blockage
    Wulan Li et al, 2016, Anti-Cancer Drugs CrossRef